TNFR2 is one of two receptors for tumor necrosis factor alpha (TNF-α), and it sits at a crossroads in the immune system: the same receptor that helps keep inflammation in check can also shield tumors from immune attack. That duality makes it one of the more intriguing therapeutic targets in immunology right now, with researchers developing drugs that either activate or block TNFR2 depending on whether the goal is to dampen autoimmune inflammation or unleash an antitumor response.
What Makes TNFR2 Different From TNFR1
TNF-α works through two receptors, TNFR1 and TNFR2, but the two behave very differently. TNFR1 is found on virtually every cell type and carries a “death domain” in its intracellular tail, meaning it can trigger programmed cell death. TNFR2, by contrast, lacks that death domain and is expressed more selectively, mainly on immune cells, certain brain cells, and endothelial cells lining blood vessels. Instead of initiating cell death, TNFR2 generally promotes cell survival and proliferation. When activated, it recruits a signaling complex that turns on pathways associated with keeping cells alive and dampening inflammation.
The two receptors also differ in what activates them. TNFR1 responds well to soluble TNF-α, the form that gets clipped off cell surfaces and circulates freely. TNFR2, on the other hand, is preferentially activated by membrane-bound TNF-α, the version still anchored to the cell that produced it. Research has shown that TNFR2’s stalk region actively inhibits the receptor from clustering in the membrane and from assembling into signaling-ready complexes in response to soluble TNF, which blocks soluble-TNF-driven signaling while leaving membrane-bound TNF signaling intact.1Molecular and Cellular Biology. The tumor necrosis factor receptor stalk regions define responsiveness to soluble versus membrane-bound ligand This selectivity matters because it means TNFR2 tends to get activated during direct cell-to-cell contact rather than by the diffuse inflammatory signals that TNFR1 picks up.
Once activated, TNFR2 weakly associates with a signaling complex involving TRAF2 and cIAP proteins, which in turn activates a branch of the NF-κB pathway called the noncanonical pathway. It also promotes survival through the PI3K/Akt pathway and downstream STAT5 signaling, and can form a complex with a tyrosine kinase called Etk/Bmx alongside VEGFR2, linking TNFR2 activity to blood vessel growth.2Nature. Inflammation and cancer cell survival: TRAF2 as a key player The upshot is that TNFR2 signaling is broadly pro-survival and anti-inflammatory, which is exactly what makes it both beneficial and exploitable.
TNFR2 as an Immune Peacekeeper
The most studied role of TNFR2 on the protective side is its relationship with regulatory T cells, or Tregs. These are the immune cells that prevent your own immune system from attacking healthy tissue. TNFR2 is highly expressed on Tregs, and research has shown that it is critical for maintaining their stability, particularly under inflammatory conditions where Tregs are most needed.
In mice lacking TNFR2, the proportion of Tregs in the thymus and lymphoid tissues was reduced. More telling, when purified Tregs were activated in lab conditions, they tended to lose expression of Foxp3, the master regulator that defines their suppressive identity. Adding TNF-α partially prevented that loss, and blocking TNFR2 with an antibody eliminated TNF’s protective effect, while blocking TNFR1 had no such impact. In a mouse colitis model, Tregs lacking TNFR2 were unable to control the disease the way normal Tregs could, and many of those TNFR2-deficient Tregs lost their Foxp3 expression in inflamed gut tissue.3The Journal of Immunology. TNFR2 Is Critical for the Stabilization of the CD4+Foxp3+ Regulatory T Cell Phenotype in the Inflammatory Environment In plain terms, TNFR2 helps Tregs stay Tregs when inflammation would otherwise cause them to lose their identity.
TNFR2 also influences another class of immunosuppressive cells called myeloid-derived suppressor cells, or MDSCs. These cells help tamp down immune responses and are found in both healthy tissues and tumor environments. TNFR2 activation through membrane-bound TNF has been shown to promote the suppressive activity of MDSCs and to increase their production of immune-dampening molecules like interleukin-10.4PubMed. TNFR2: Its Dual Role in Immune Health and Disease When TNFR2 is absent, MDSC-mediated suppression of T cells drops. This is a double-edged sword: in autoimmune diseases, boosting MDSC activity could be therapeutic, but in cancer, it represents one way tumors avoid immune destruction.
How Tumors Hijack TNFR2
The same immunosuppressive machinery that protects healthy tissue from autoimmune damage can be co-opted by tumors. Cancer cells frequently sit in a microenvironment rich in Tregs and MDSCs, both of which express high levels of TNFR2. These immunosuppressive cells help the tumor evade detection by killer T cells and natural killer cells. TNFR2 has been linked to both Treg induction and MDSC accumulation in the tumor microenvironment, contributing to the immunosuppressive landscape that allows tumors to grow unchecked.5The Journal of Immunology. Transmembrane TNF-α Promotes Suppressive Activities of Myeloid-Derived Suppressor Cells via TNFR2
Some tumor cells also express TNFR2 on their own surfaces, directly benefiting from its pro-survival signaling. TNFR2 was first proposed as a promising tumor immune target in 2017, and since then evidence has accumulated that it not only promotes tumor cell proliferation but also correlates with the suppressive function of Tregs within tumors.6PubMed Central. Targeting TNFR2 for cancer immunotherapy: recent advances and future directions Beyond Tregs and MDSCs, TNFR2 signaling affects other cell types that shape the tumor’s immune landscape, including endothelial cells and endothelial progenitor cells that feed tumor blood supply, as well as CD8+ killer T cells and NK cells.7PubMed Central. TNFR2: Role in Cancer Immunology and Immunotherapy
Blocking TNFR2 to Unleash Antitumor Immunity
If TNFR2 helps build the immunosuppressive shield around tumors, then blocking it could strip that shield away. Several approaches to TNFR2 antagonism are now in development. In mouse models of pancreatic cancer, blocking TNFR2 with a monoclonal antibody reduced the number of Tregs infiltrating the tumor and improved the balance between effector T cells and Tregs, tilting the microenvironment toward antitumor immunity.8Journal for ImmunoTherapy of Cancer. TNFR2 blockade promotes antitumoral immune response in PDAC by targeting activated Treg and reducing T cell exhaustion
A particularly interesting recent development is a biparatopic antagonist, an antibody that binds two different spots on TNFR2 simultaneously. In a TNFR2-humanized colon cancer mouse model, this antagonist produced dose-dependent tumor growth inhibition comparable to a benchmark antibody. What stood out was that the antitumor effect was fully preserved even in a version of the antibody engineered to be “effector-silent,” meaning it could not trigger immune-cell-mediated killing through its Fc region. The therapeutic effect came purely from blocking TNFR2 signaling.9Journal of Leukocyte Biology. A TNFR2 biparatopic antagonist reverses immune suppression through a crosslinking-resistant and ADCC-independent mechanism That finding is encouraging because it suggests the approach could work without the off-target toxicity that Fc-mediated killing sometimes brings.
Activating TNFR2 to Calm Autoimmune Disease
While oncologists want to block TNFR2, immunologists treating autoimmune diseases want to do the opposite. The logic is straightforward: if TNFR2 activation expands Tregs and boosts their suppressive power, then a drug that selectively stimulates TNFR2 could dial down the overactive immune response behind conditions like rheumatoid arthritis, inflammatory bowel disease, or type 1 diabetes. TNFR2 agonists have been investigated as potential therapies for inflammatory diseases specifically because of their ability to expand Tregs and MDSCs.10PubMed Central. Therapeutic potential of TNFR2 agonists: a mechanistic perspective
One newly characterized TNFR2 agonist antibody expanded the number of Tregs in cultures of human CD4+ T cells from healthy donors and patients with type 1 diabetes or Sézary syndrome, a rare T-cell lymphoma. The expanded Tregs showed metabolic characteristics associated with maximally suppressive, anti-inflammatory function and were able to repress the activity of CD8+ effector T cells.11PubMed. A novel TNFR2 agonist antibody expands highly potent regulatory T cells These are still preclinical results, but they point toward a therapeutic strategy that could complement or even replace current anti-TNF therapies in some situations.
That replacement angle matters because current anti-TNF drugs, the backbone of treatment for diseases like rheumatoid arthritis and Crohn’s disease, block TNF indiscriminately. They shut down both TNFR1-mediated inflammatory signals and TNFR2-mediated immunosuppressive signals, and in some TNF-driven diseases, anti-TNF blockers are either ineffective or actually worsen the disease course. One explanation is that these drugs inadvertently neutralize the TNFR2 signaling that was keeping things from getting even worse.12Journal of Leukocyte Biology. TNFR2-targeting biologics: Molecular mode of action, possible applications, and future developments Drugs that selectively target one receptor or the other could avoid that problem.
The Role of TNFR2 in Inflammatory Bowel Disease
Gut inflammation offers a vivid case study of TNFR2’s dual personality. In human ulcerative colitis and Crohn’s disease, TNFR2 expression is upregulated on colonic epithelial cells, and in mouse models, TNFR2-deficient animals showed less colonic epithelial proliferation, suggesting the receptor contributes to the tissue remodeling that drives chronic intestinal inflammation.13PubMed. Role of tumor necrosis factor receptor 2 (TNFR2) in colonic epithelial hyperplasia and chronic intestinal inflammation in mice At the same time, TNFR2-deficient CD4+ T cells produced fewer inflammatory mediators and were less pathogenic in models of both colitis and experimental autoimmune encephalomyelitis, a model of multiple sclerosis.14PubMed Central. TNF plays a crucial role in inflammation by signaling via T cell TNFR2
So TNFR2 appears to do two things in the inflamed gut: it drives some of the tissue remodeling and immune activation that perpetuate disease, while also maintaining the Treg population that tries to resolve it. Which effect dominates likely depends on the stage of disease, the specific cell types involved, and how much membrane-bound versus soluble TNF is present. This is part of why simple TNF blockade does not work equally well for everyone with inflammatory bowel disease.
Neuroprotection and Brain Disease
The brain is another tissue where TNFR2’s protective side becomes especially important. In the central nervous system, the two TNF receptors play fundamentally different roles. TNFR1, together with its downstream signaling, promotes harmful microglial activation and tissue injury during demyelination. Neuronal TNFR2, on the other hand, is protective: in a mouse model of excitotoxicity induced by kainic acid, neuronal TNFR2 limited hippocampal neuron death. That protection involved a relay where astrocyte TNFR1 signaling led to production of membrane-bound TNF, which then acted on neuronal TNFR2 to deliver the protective signal. The effect could be reproduced using a TNFR2-specific agonist.15PubMed Central. Fundamentally different roles of neuronal TNF receptors in CNS pathology: TNFR1 and IKKβ promote microglial responses and tissue injury in demyelination while TNFR2 protects against excitotoxicity in mice
TNFR2 also plays a role in the cells that produce myelin, the insulation around nerve fibers. In oligodendrocyte precursor cells, TNFR2 signaling dampened their immune-inflammatory activation and suppressed the toxic reactivity of nearby microglia during demyelinating disease.16PubMed Central. TNFR2 signaling in oligodendrocyte precursor cells suppresses their immune-inflammatory function and detrimental microglia activation in CNS demyelinating disease These findings are relevant to conditions like multiple sclerosis, where both neuronal damage and myelin loss are central problems. The implication is that drugs blocking TNF across the board might inadvertently strip away TNFR2-mediated neuroprotection, which could explain why anti-TNF therapies have sometimes worsened MS symptoms in clinical experience.
Blood Vessel Growth and Tissue Repair
Outside the immune system, TNFR2 has a notable role in growing new blood vessels. In a mouse model of hindlimb ischemia, where blood flow is cut off and the tissue needs to grow new vessels to survive, mice engineered to overexpress TNFR2 specifically in endothelial cells showed significantly enhanced arteriogenesis, the formation of larger blood vessels, as well as increased capillary formation and maturation. This was associated with reduced cell death and increased proliferation, driven by TNFR2-dependent activation of the Bmx-VEGFR2 signaling pathway.17PubMed Central. Endothelial-specific Transgenesis of TNFR2 Promotes Adaptive Arteriogenesis and Angiogenesis
TNFR2 also affects endothelial progenitor cells, the bone-marrow-derived cells that contribute to vascular repair. Priming these cells with a low dose of TNF-α before transplanting them boosted their immunosuppressive phenotype through TNFR2, potentially allowing them to survive longer after transplantation and contribute more effectively to blood vessel regeneration.18PubMed Central. TNFα priming through its interaction with TNFR2 enhances endothelial progenitor cell immunosuppressive effect: new hope for their widespread clinical application For tissue engineering and regenerative medicine, this link between TNFR2 and vascular repair is an underappreciated asset.
Cross-Talk Between the Two TNF Receptors
TNFR1 and TNFR2 do not operate in isolation. The signaling pathways they initiate influence each other, and the timing of that cross-talk matters. Research has revealed that the complexity of this interplay is shaped by different signaling kinetics between the two receptors, creating a delicate balance between cell survival and cell death.19PubMed. Tumor necrosis factor receptor cross-talk In some contexts, TNFR2 activation can deplete the TRAF2 and cIAP proteins that TNFR1 needs to signal for survival, paradoxically sensitizing cells to TNFR1-mediated death. In other settings, TNFR2 provides a strong survival signal that overrides TNFR1’s death signal. Which outcome wins depends on the relative expression levels of each receptor, the cell type, and whether TNF is presented in soluble or membrane-bound form.
This cross-talk also extends to immune surveillance during infections. In NK cells responding to bacterial infection, TNFR1 and TNFR2 have overlapping but distinct functions. TNFR1 primarily plays an inhibitory role, limiting NK cell accumulation through cell death, while TNFR2 is protective and promotes NK cell accumulation. In mice, TNFR1 deficiency reduced bacterial burden in the spleen, whereas TNFR2 deficiency increased bacterial burden in the liver.20Nature Communications. Dichotomous outcomes of TNFR1 and TNFR2 signaling in NK cell-mediated immune responses during inflammation The two receptors are not simply pro-inflammatory versus anti-inflammatory; they divide up the labor of immune defense in tissue-specific ways.
Soluble TNFR2 as a Built-In Regulator
Your body has a built-in feedback mechanism for TNFR2 signaling. The extracellular portion of TNFR2 can be cleaved off the cell surface by an enzyme called ADAM17, releasing a soluble fragment that floats freely and can mop up TNF-α in the surrounding environment. In CD8+ T cells responding to influenza infection, ADAM17 was identified as the protease responsible for this shedding, and the shedding required both ADAM17 and TNFR2 to be present on the same cell. The activation thresholds for producing TNF-α and for shedding TNFR2 were similar, suggesting that cells release soluble TNFR2 at the same time they produce TNF-α as a way to keep local TNF levels from getting out of hand.21PubMed Central. Shedding of TNF receptor 2 by effector CD8⁺ T cells by ADAM17 is important for regulating TNF-α availability during influenza infection
Soluble TNFR2 levels in the blood have attracted interest as a biomarker for inflammatory and autoimmune conditions, though its clinical utility is still being worked out. The principle is that elevated shedding reflects elevated TNF signaling, which in turn reflects active inflammation.
Genetic Variation and Why Anti-TNF Drugs Do Not Work for Everyone
The gene encoding TNFR2, called TNFRSF1B, carries polymorphisms that influence who responds well to anti-TNF therapy and who does not. A meta-analysis found that TNFRSF1B polymorphisms are associated with response or non-response to anti-TNF therapy across multiple autoimmune diseases, including rheumatoid arthritis, psoriasis, and Crohn’s disease.22PubMed. The tumor necrosis factor receptor superfamily member 1B polymorphisms predict response to anti-TNF therapy in patients with autoimmune disease: A meta-analysis One specific polymorphism, rs767455, was associated with the risk of developing ankylosing spondylitis in Chinese Han patients who carry the HLA-B27 gene, with carriers of the G allele showing a roughly 63% higher odds of developing the disease.23PubMed Central. Role of TNFRSF1A and TNFRSF1B polymorphisms in susceptibility, severity, and therapeutic efficacy of etanercept in human leukocyte antigen-B27-positive Chinese Han patients with ankylosing spondylitis
These findings feed into the broader push toward personalizing anti-TNF treatment. If your genetic variant of TNFR2 makes you less responsive to a blanket TNF blocker, a drug that selectively targets one receptor might be more effective. This is still early-stage translation, but the genetics underscore that TNFR2 biology varies from person to person in ways that have real clinical consequences.
How Aging Shifts TNFR2 Expression
The balance between TNFR1 and TNFR2 expression is not fixed over a lifetime. A study examining TNF receptor expression across different immune cell types found that the proportion of TNFR2-positive T cells increased with age, while TNFR1-positive and TNFR2-positive monocyte populations both declined.24PubMed Central. Nonlinear Dynamics of TNFR1 and TNFR2 Expression on Immune Cells: Genetic and Age-Related Aspects of Inflamm-Aging Mechanisms The rising TNFR2 on T cells with age could be the immune system’s attempt to compensate for the chronic low-grade inflammation that characterizes aging, sometimes called inflammaging. More TNFR2 on T cells could mean a greater push toward regulatory, suppressive function. But the simultaneous loss of TNFR2 on monocytes complicates that picture, since monocytes are front-line innate immune cells and their response to TNF signaling also matters.
The practical takeaway is that TNF-targeting therapies developed and tested primarily in middle-aged adults might not behave identically in older patients, whose receptor landscape has shifted. This is an area where age-stratified clinical trials would be valuable but are rarely conducted.
Engineering TNFR2-Specific Drugs
Designing drugs that selectively activate or block TNFR2 without affecting TNFR1 is a major engineering challenge. For agonists, the goal is to mimic the clustering effect of membrane-bound TNF. Researchers have found that the domain architecture of an antibody construct is the most important factor determining whether it can activate TNFR2 without needing to be cross-linked by Fc receptors on other cells. Antibody formats with TNFR2-binding sites on opposing sides of the scaffold, or with six or more binding sites in similar orientation, consistently showed strong activity independent of Fc receptors. The affinity of the binding domain and the exact spot on TNFR2 it targeted turned out to be secondary considerations.25PubMed Central. Generic design principles for antibody-based tumour necrosis factor (TNF) receptor 2 (TNFR2) agonists with FcγR-independent agonism
For antagonists, the challenge is the opposite: bind TNFR2 without accidentally triggering it. One approach uses biparatopic antibodies that target two distinct spots on TNFR2 simultaneously. By carefully selecting which two epitopes to target, researchers can control the size of the antibody-receptor complexes that form and thus regulate whether the complex triggers signaling. One particular biparatopic antagonist, Bp109-92, binds TNFR2 in a 1:1 manner, preventing the receptor clustering needed for signal transduction. Its structural basis has been confirmed by cryo-electron microscopy.26Communications Biology. Development of a 1:1-binding biparatopic anti-TNFR2 antagonist by reducing signaling activity through epitope selection Getting this geometry right is the difference between a drug that blocks TNFR2 and one that accidentally stimulates it, which would be the worst possible outcome in a cancer patient.
The field is essentially trying to build a set of precision tools for a receptor that evolution designed to be context-dependent. Whether those tools reach patients will depend on clinical trials that can navigate the paradox at the heart of TNFR2 biology: the same receptor that restrains autoimmunity also enables tumor immune evasion, and any drug that touches it will need to thread that needle in a disease-specific way.